A diagnostic system detects and/or measures hemoglobin variants in blood of subject, such as HbA1c, to determine blood glucose concentration in the subject.

A method of measuring stable A1c in a blood sample based on a time distribution of an optical measured value of hemoglobin at a flow path which separates hemoglobin in the blood sample on a basis of amounts of the charges of hemoglobin is provided. The method may include a step of obtaining a correction factor, based on a peak area (A) of a fraction including HbA0 and either a peak area (G) of a first fraction including chemically-modified HbA0, or a peak area (D) of a second fraction including a component having a smaller amount of positive charge than HbA0 adjacent to a fraction identified as HbA0, in the time distribution; and a step of correcting, based on the correction factor a peak area of a fraction including stable A1c in the time distribution.

The present invention relates to improvements in female health monitoring and treatment wherein menstrual blood samples are analyzed for biomarkers of interests to monitor the health status and treatment of a female patient.

A method of spectroscopically measuring percent glycated hemoglobin or a glycated hemoglobin:total hemoglobin ratio in a biological sample is disclosed. The method includes the use of a turbidity normalization algorithm to normalize the total hemoglobin concentration calculated from the spectroscopic measurements to substantially remove any turbidity interference therefrom. The turbidity normalization eliminates the negative bias observed with intralipid/lipemia and thus provides a glycated hemoglobin assay with no significant interference from intralipid/lipemia.

A method of spectroscopically measuring percent glycated hemoglobin or a glycated hemoglobin:total hemoglobin ratio in a biological sample is disclosed. The method includes the use of a turbidity normalization algorithm to normalize the total hemoglobin concentration calculated from the spectroscopic measurements to substantially remove any turbidity interference therefrom. The turbidity normalization eliminates the negative bias observed with intralipid/lipemia and thus provides a glycated hemoglobin assay with no significant interference from intralipid/lipemia.

Electrochemical test sensors and analysis methods are described that reduce or eliminate the pre-treatment or dilution of blood samples prior to HbA1c analysis. Thus, a blood sample obtained from a blood draw or phlebotomy may be introduced to the electrochemical test sensor for HbA1c analysis. The described test sensors immobilize or deactivate incompatible reagents, enzymes, and antibodies so they do not substantially interfere with each other during the analysis. The test sensors also use heat to catalyze reactions that otherwise would proceed at too slow of a rate to be practical.

Provided is a reagent composition for measuring glycated hemoglobin to diagnose the presence or absence of diabetes and a method of measuring glycated hemoglobin using the same, and more particularly is a reagent composition for measuring glycated hemoglobin, the composition including a dye-encapsulated silica nanoparticle-boronic acid, and to a method of measuring glycated hemoglobin using the same. In the reagent composition for measuring the glycated hemoglobin, since a dye is encapsulated in silica nanoparticles, the inherent absorption wavelength of the dye is not affected by pH and the composition has excellent stability even when stored for one month or more.

The present invention refers to a method for determining peptide fragments of glycated hemoglobin A (HbA1c) molecules by mass spectrometry (MS), a reagent kit, and a clinical diagnostic system adapted for performing the method.

The present invention refers to a method for determining intact glycated hemoglobin A (HbA1c) by mass spectrometry (MS), a kit and a diagnostic system adapted for performing the method.

A single-channel, chemical-immunological hybrid biosensor is disclosed. According to an embodiment, the hybrid biosensor includes a reaction strip 100 in the form of a porous membrane through which a sample 1 moves by capillary action. the reaction strip 100 is in the form of a porous membrane through which the sample 1 moves by capillary action. Biomarkers in the sample 1 are independently detected based on a chemical reaction and binding reactions on the reaction strip 100.